x

Posted 05 August, 2021

Black Diamond Therapeutics, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:BDTX in a 8-K filed on 05 August, 2021.


  Effective August 11, 2021, Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Black Diamond Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Market Cap
$232M
View Company Details
Black Diamond Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On August 3, 2021, Black Diamond Therapeutics, Inc. (the "Company") appointed Karsten Witt, M.D., the Company's Senior Vice President of Clinical Development, Interim Chief Medical Officer until a permanent successor is appointed.


Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021.


The Company has offered Dr. Humphrey a separation agreement (the "Separation Agreement") in connection with the termination of her employment pursuant to which Dr. Humphrey will receive severance pay and benefits in accordance with her employment agreement and serve as an advisor to the Company until February 28, 2022 (the "Advisory Period"). The Separation Agreement also extends the exercise period for any vested stock options held by Dr. Humphrey until the 12-month anniversary of the last day of the Advisory Period.


On August 3, 2021, the Company also appointed Elizabeth Buck, Ph.D., the Company's Co-Founder and Executive Vice President, Discovery & Translational Sciences, Chief Scientific Officer.


Effective August 11, 2021, Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company. Dr. Roberts will serve as an advisor to the Company following his departure.